• Wonder

  Participated · Equity · Mar 2024

  Wonder builds a vertically integrated food technology platform combining chef-developed concepts, third-party restaurant marketplace listings and at-home meal kits in a single customer experience. Its proprietary kitchen technology includes the Infinite Kitchen and the only fully automated bowl-making system in live commercial production, and the platform supports multi-restaurant ordering within a single order. The company has expanded rapidly, reporting its footprint tripled from 46 to 140 locations since May 2025. Wonder is investing in robotics, artificial intelligence and delivery infrastructure, including a partnership with Zipline to pilot on-demand drone delivery in Texas. Marc Lore is founder and CEO, and the company positions itself to own mealtime from recipe development through autonomous delivery. Financially, the company raised $650 million in a Series D at a $9 billion pre-money valuation to fund its expansion and technology investments.

• Timeline

  Participated · Series D · Jan 2024

  Timeline (parent company Amazentis) is a Lausanne-based consumer health biotech focused on Mitopure®, a proprietary ingredient designed to improve mitochondrial function and support healthy aging. Mitopure® is backed by over 15 years of research, multiple clinical studies and more than 50 patents and is clinically proven to target a cellular longevity pathway. Timeline incorporates Mitopure® into next-generation nutritional supplements and topical skin health products. The company plans to expand its science, product categories, and markets across food, beauty, and health sectors and to build the brand in consumer longevity. Nestlé Health Science has been an investor since 2019. Timeline recently completed a significant financing to support these growth plans. Based in Lausanne, Switzerland, Amazentis develops products targeting mitochondrial health for advanced nutrition and pharmaceutical applications. Its proprietary lead product candidate, AMAZ-02, is an oral formulation of urolithin A that stimulates mitophagy to improve mitochondrial function in muscle. The company has reported preclinical results in Nature Medicine and presented Phase 1 clinical safety and translational data. Amazentis has established an extensive intellectual property portfolio and proprietary know‑how around urolithin A. With the recently completed Series C financing, the company plans to advance two pivotal Phase 2 trials (ENERGIZE and ATLAS) and to prepare for future commercial activities. The clinical program is focused on validating AMAZ-02 as a solution to support healthy aging and improve muscle function.

• Sundial Foods

  Participated · Seed · Nov 2021

  Sundial Foods uses a proprietary protein-structuring process to recreate whole chicken wings from plant ingredients, including skin, muscle and bone. Its first product is a whole-cut vegan chicken wing made with just eight ingredients and no synthetic additives. The company emphasizes less heavy processing than many plant-based meats, leveraging intrinsic starches and fibers to generate fibrous texture and a cohesive three-dimensional product in one shot. Co-founders Jessica Schwabach and Siwen Deng say the method avoids later assembly and focuses on automating production. Sundial plans to launch in Bay Area restaurants in spring 2022 before expanding to other US locations and will commence production at the Rutgers Food Innovation Center in Bridgeton, New Jersey. The $4M seed will fund team expansion and production scale-up as it prepares for market entry.

• Cerecin

  Participated · Series A · Oct 2021

  Cerecin focuses on creating therapeutics that address the metabolic basis of central nervous system diseases. Its lead candidate, CER-0001, is being evaluated in clinical studies for migraine prevention and infantile spasms, with plans for a pivotal Alzheimer’s disease trial. The company recently completed enrollment of the 83-patient RELIEF pilot migraine study and is expanding its infantile spasms trial sites in Australia and Singapore. Proceeds from recent financings are earmarked to advance these programs and to broaden Cerecin’s pipeline of lipid-based neurotherapeutics. Cerecin benefits from strategic backing by Nestlé S.A. and Wilmar International, along with a network of Korean institutional investors. Although no revenue figures have been disclosed, the firm closed a USD $40 million Series II/IIA round in late 2021 and continues to secure follow-on capital to reach upcoming clinical inflection points.

• Terracycle

  Participated · Series A · Dec 2020

  Founded in 2001 and based in Trenton, N.J., TerraCycle US builds and scales recycling solutions for materials not typically accepted in curbside programs, covering hundreds of waste streams such as snack wrappers, coffee pods, cosmetics, pet food bags, and car seats. The company reported growing U.S. revenue 75% over four years, from $24.7 million in 2020 to $43.1 million in 2024, and generated $19.3 million in gross profit in 2024 while remaining consistently profitable. TerraCycle US has completed three strategic acquisitions since 2018 to expand operational capabilities and strengthen its market position, and it has partnered with major brands and retailers including P&G, Nestle, and Walmart. The broader TerraCycle network has collected and recycled over 8 billion items, raised $20 million for schools and nonprofits, and received numerous industry awards. The company intends to use proceeds from the Regulation A raise to fund further strategic acquisitions and disciplined growth to drive recurring revenue and durable market leadership.

No current team members are available.